Hybrid Clinical Trials Coordinator II – Cancer Research

Moffitt Cancer Center; Wesley Chapel (FL); Hybrid; USD 60,000 - 80,000; Full time

Benefits offered by this job

Relocation assistance

Paid training

Hybrid work

Job summary

Moffitt Cancer Center in Wesley Chapel, FL, is seeking a Clinical Research Coordinator II to support PI-led clinical trials. The CRC II coordinates patient care with medical staff and maintains protocol compliance under regulatory guidelines, acting as a liaison between investigators, care providers, and sponsors.

The role offers a Monday–Friday schedule with hybrid work after a 90-day training period, with relocation assistance possibly provided and paid training through the CTO Academy.

Qualifications

• Bachelor’s degree with 2 years clinical trials coordination experience.
• In lieu of a bachelor’s degree, an associate’s degree with 4 years clinical trials coordination experience.
• CCRP/CCRC certification preferred.

Responsibilities

• Support the Principal Investigator (PI) in clinical trials by implementing and coordinating research including administrative procedures.
• Serve as the primary resource for study protocols and coordinate patient care with medical staff in accordance with standards and regulatory guidelines.
• Act as liaison between investigators, care providers, Moffitt regulatory staff and the sponsor.

Skills

Clinical trials coordination

Regulatory compliance

Documentation

Education

Bachelor’s degree in a related field

Associate degree in a related field

Job description

Moffitt Cancer Center in Wesley Chapel, FL, is seeking a Clinical Research Coordinator II to support PI-led clinical trials. The CRC II coordinates patient care with medical staff and maintains protocol compliance under regulatory guidelines, acting as a liaison between investigators, care providers, and sponsors.

The role offers a Monday–Friday schedule with hybrid work after a 90-day training period, with relocation assistance possibly provided and paid training through the CTO Academy.